Home / Precision Medicine (page 20)

Precision Medicine

Forge Therapeutics and Active Motif Enter Epigenetics Research Collaboration

SAN DIEGO, March 28, 2016 /PRNewswire/ — Forge Therapeutics, Inc., a biotechnology company discovering innovative therapeutics using a breakthrough drug discovery platform targeting metalloproteins, and Active Motif, a leader in developing tools to enable epigenetics research, announced today a research collaboration aimed at advancing epigenetic research related to the family …

Read More »

Lupus Study Shows Precision Medicine’s Potential to Define the Genetics of Autoimmune Disease

DALLAS – March 18, 2016 – Demonstrating the potential of precision medicine, an international study based at UT Southwestern Medical Center used next-generation DNA sequencing technology to identify more than 1,000 gene variants that affect susceptibility to systemic lupus erythematosus (SLE). Precision medicine is an emerging field that aims to deliver …

Read More »

Contextual Genomics and the Personalized Medicine Initiative Launch Mid-Stage Testing of its National Access Program Cancer Genomics Test

VANCOUVER, British Columbia–(BUSINESS WIRE)–Contextual Genomics, developers of genomics-based cancer tests, and the Personalized Medicine Initiative (PMI), an organization bringing molecular-based medicine to Canadians, are pleased to announce they have launched the National Access Program’s Phase 2 Testing of its Find It™ (CG001) hotspot cancer panel genomics test. The National Access …

Read More »

Molecular Therapy Highlights Sleeping Beauty Potential in Personalized TCR Gene Therapy

BOSTON, March 09, 2016 (GLOBE NEWSWIRE) — ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announced the publication of an article describing the use of Sleeping Beauty non-viral gene transfer technology to modify T cells for the targeting of neoantigens present within solid tumors. This …

Read More »

Surescripts Supports White House to Advance Precision Medicine Initiative

ARLINGTON, Va.–(BUSINESS WIRE)–Today Surescripts, the nation’s leading health information network, announces its support of President Obama’s Precision Medicine Initiative (PMI). Surescripts will participate in the White House Precision Medicine Initiative Summit and pledge its support to provide Surescripts’ infrastructure and technology to help the Precision Medicine Initiative aggregate the medical …

Read More »

Baxalta and Precision Biosciences Form Global Genome Editing Collaboration in Immuno-Oncology

BANNOCKBURN, Ill. & DURHAM, N.C.–(BUSINESS WIRE)–Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, and Precision BioSciences, the genome editing company, today announced a global collaboration to develop a broad series of allogeneic chimeric antigen receptor (CAR) T …

Read More »

Regen BioPharma Completes Preclinical Experimentation of its Novel siRNA NR2F6 Checkpoint Inhibitor

SAN DIEGO, February 24, 2016 /PRNewswire/ — Regen BioPharma, Inc., (OTCBB: RGBP) and (PINK: RGBP) announced today completion of experiments, in collaboration with Dr.Santosh Kesari, demonstrating immunological mechanisms of its novel NR2F6 gene silencing approach.  Subsequent to these experiments, the Company has begun the process of compiling an Investigational New Drug …

Read More »

ImmunID and Memorial Sloan Kettering Partner to Validate Cancer Immunotherapy Companion Diagnostic

GRENOBLE, France, Feb. 23, 2016 /PRNewswire/ — ImmunID, the immune companion diagnostics for precision medicine company, today announces that it has just signed a master collaboration agreement with Memorial Sloan Kettering Cancer Center (MSK) in New York, United States. MSK is the world’s oldest and largest private cancer center. It has ranked …

Read More »

Myriad Expands Diagnostic Research Collaboration with TESARO and Merck

SALT LAKE CITY, Feb. 22, 2016 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced a strategic research collaboration with TESARO and Merck, known as MSD outside the U.S. and Canada, to help identify potential responders to an investigational combination drug therapy …

Read More »